Emerging problems regarding severity assessment and treatment strategies for patients with pneumonia: controversies surrounding the HCAP concept

Yuichiro Shindo • Yoshinori Hasegawa

In this issue of Internal and Emergency Medicine, Falcone et al. [1] validate the widely used predictive scoring systems for assessing the severity of pneumonia. These include the Pneumonia Severity Index (PSI) [2], CURB-65 (confusion, uremia, respiratory rate, low blood pressure, 65 years of age or older) [3], and severe community-acquired pneumonia (SCAP) scores [4] for hospitalized patients with community-acquired pneumonia (CAP) and health care-associated pneumonia (HCAP) who were enrolled in a prospective multicenter cohort study in Italy [5]. The authors find that PSI, CURB-65, and SCAP scores have a good performance for patients with CAP, but are less useful for patients with HCAP, particularly those categorized as low risk. Furthermore, they describe that inclusion in the severe classes of PSI, CURB-65, and SCAP scores and receiving an empirical treatment that does not adhere to international guidelines, as documented in the 2005 or 2007 American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) [6, 7], prove to be risk factors independently associated with in-hospital mortality or development of adverse events, including death, septic shock, and the need for a transfer to an intensive care unit (ICU).

When the PSI, CURB-65, and SCAP scores were developed, the concept of HCAP was not widely used. Thus, a substantial number of HCAP patients were previously defined as having CAP. A Japanese retrospective study shows that areas under the receiver operating characteristic curves for the 30-day mortality in predictive rules, including those for CURB-65, are greater in patients with newly defined CAP [7], in which HCAP is excluded, than in those with previously defined CAP [8]. This study shows similar results; high proportions of mortality and adverse events among HCAP patients with low severity

Y. Shindo and Y. Hasegawa contributed equally to this work.

Y. Shindo
The Institute for Advanced Research, Nagoya University, Nagoya, Japan

Y. Shindo (✉) • Y. Hasegawa
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
e-mail: yshindo@med.nagoya-u.ac.jp
scores determined by PSI, CURB-65, and SCAP suggesting that the predictive rules for CAP are not useful for patients with HCAP. Over the past several years, the reasons for why HCAP should be distinguished from CAP have been based on evidence that the proportion of occurrence of potentially drug-resistant (PDR) pathogens [e.g., *Pseudomonas aeruginosa*, extended-spectrum β-lactamase-producing Gram-negative bacteria, and methicillin-resistant *Staphylococcus aureus* (MRSA)] and the receipt of inappropriate empirical treatments in HCAP patients are higher than those in CAP patients [9, 10]. Therefore, the results of this study provide a different perspective to support the necessity for using the HCAP concept as a distinct entity.

Why are PSI, CURB-65, and SCAP scores not useful for patients with HCAP? The reasons may depend on the following: (1) there may be confounding factors related to mortality or adverse events that are not included in their predictive rules (e.g., parameters for activities of daily living) and (2) cut-off values for continuous variables that are included in these rules are different for patients with CAP and HCAP. Moreover, it is undeniable that treatment restrictions for patients with HCAP exist, as pointed out by Ewig et al. [11]. Therefore, additional studies designed to analyze risk factors for mortality or adverse events in patients with HCAP are required considering the above factors.

Falcone et al. describe that the receipt of an empirical treatment that does not adhere to international guidelines is a risk factor independently associated with in-hospital mortality or development of adverse events. Several studies suggest improved outcomes among hospitalized CAP patients who are treated according to the CAP guidelines as opposed to those treated with a guideline-discordant regimen [12]. However, a possible association between adherence to the 2005 or 2007 ATS and IDSA guidelines for empirical antibiotic treatment and poor outcome is controversial; particularly, for patients with HCAP [12]. In fact, there is evidence showing an association between mortality and inappropriate empirical antibiotic treatment, defined as not receiving antibiotics with in vitro activity against offending pathogens [10]. Furthermore, several reports show that HCAP patients infected with PDR pathogens are at high risk for inappropriate empirical antibiotic treatment [9, 10, 13]. This inappropriate empirical antibiotic treatment may be close to the empirical treatment that does not adhere to the 2005 or 2007 ATS and IDSA guidelines. However, Kett et al. [6, 14] recently report that compliance with the 2005 ATS/IDSA guidelines is associated with increased mortality, which has raised important questions for current recommendations for the management of nosocomial pneumonia in patients at risk for multidrug-resistant (MDR) pathogens that call for prompt broad-spectrum empirical treatment. In addition, a validation study by Nseir et al. [15] reports that the 2005 ATS/IDSA criteria for predicting infection or colonization related to MDR bacteria have a low positive predictive value, but an excellent negative predictive value, at ICU admission. Therefore, the recommendations in the 2005 ATS/IDSA guidelines remain controversial.

One group of researchers has disagreed with the concept of HCAP because it may mislead physicians into the administration of unnecessary broad-spectrum antibiotics [11]. In addition, it has been considered that HCAP should be broken down into several distinct subgroups in order to be able to use narrow-spectrum antibiotics [16]. However, physicians should at least be aware of those patients who are more likely to receive inappropriate empirical antibiotic treatment than patients with CAP because of the possible PDR pathogens, and should be able to distinguish these patients, like those with HCAP, from those with CAP [9, 10, 12, 13, 17].

We should pay attention to the fact that PDR or MDR pathogens may not be the infectious agents in all patients with HCAP, if we choose to identify patients with HCAP [18]. That is, for patients with HCAP, there are both patients those who require broad-spectrum antibiotics and those who do not. Even if the definition of HCAP is further elucidated, this issue will probably persist. Furthermore, we must consider that the incidence of PDR pathogens occurrence is different in different countries and institutions [19]. There have been few prospective studies that have addressed the question, “Who should receive broad-spectrum antibiotics, and who does not need them among patients with HCAP?” Therefore, additional research is needed.

One important aim is to be able to appropriately manage patients with pneumonia, including antibiotic selection and systemic management (e.g., for complications, nutritional care, and prevention of aspiration). To achieve this aim, how should we assess or classify patients with pneumonia? This study has raised important concerns related to the assessment of severity for patients with pneumonia and the appropriate treatment strategies. The management of patients with pneumonia has changed over time. We are now facing a new era for reconsidering the management of patients with pneumonia.

**Conflict of interest** None.

**References**